MicuRx Pharmaceuticals
This article was originally published in Start Up
Executive Summary
Like numerous other companies working to develop novel anti-bacterial drugs, MicuRx Pharmaceuticals Inc. aims to modify existing chemical scaffolds to come up with better compounds. The start-up is particularly interested in four scaffolds known to inhibit protein synthesis-a common mechanism of action for anti-bacterial drugs. While the company's CEO and CSO-both of whom were among the scientific founders of Vicuron Pharmaceuticals--can offer much from their personal experience, MicuRx is carefully mining medical literature for insights and observations that can inform specific modifications to drug molecules.
You may also be interested in...
Antibiotics Start-Ups
Antibiotic R&D has always been one of the most challenging areas in biopharmaceutical drug development. Designing novel drugs that deter bacterial resistance is a technical hurdle to be sure, but it's also a commercial one: drugs doomed to rapid obsolescence don't promise a strong return on investment. There are regulatory uncertainties, too. Although FDA is now asking drug sponsors to compare the effectiveness of products against a placebo or marketed drug for some indications--for the most part, certain infections in the primary care setting--non-inferiority studies remain the norm for life-threatening infectious diseases. But the agency has yet to issue hard and fast rules on where to apply these studies and how to evaluate the use of non-inferiority margins. A recent meeting of FDA's Anti-Infective Drugs Advisory Committee provided some clarity.
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Antibiotics Start-Ups," features profiles of Indel Therapeutics, MicuRx Pharmaceuticals and Trius Therapeutics. Plus these Start-Ups Across Health Care: DFine, NexeonMedSystems, SmartCells and Somnus Therapeutics.
Antibiotics Start-Ups
Antibiotic R&D has always been one of the most challenging areas in biopharmaceutical drug development. Designing novel drugs that deter bacterial resistance is a technical hurdle to be sure, but it's also a commercial one: drugs doomed to rapid obsolescence don't promise a strong return on investment. There are regulatory uncertainties, too. Although FDA is now asking drug sponsors to compare the effectiveness of products against a placebo or marketed drug for some indications--for the most part, certain infections in the primary care setting--non-inferiority studies remain the norm for life-threatening infectious diseases. But the agency has yet to issue hard and fast rules on where to apply these studies and how to evaluate the use of non-inferiority margins. A recent meeting of FDA's Anti-Infective Drugs Advisory Committee provided some clarity.